Marius Pharmaceuticals and Hims & Hers™ Collaborate to Expand Access to KYZATREX® (testosterone undecanoate) CIII Capsules, the First FDA-Approved Oral Testosterone Therapy Offered on the Hims & Hers Platform

Core Viewpoint - Marius Pharmaceuticals has announced a collaboration with Hims & Hers to make KYZATREX®, an FDA-approved oral testosterone replacement therapy, available to patients through the Hims & Hers platform, marking a significant step in improving access to testosterone therapy for men with low testosterone levels [1][4]. Company Overview - Marius Pharmaceuticals focuses on therapies for hypogonadism or testosterone deficiency, aiming to improve metabolic health and reduce unnecessary healthcare costs [5]. - Hims & Hers is a leading digital health platform that aims to empower individuals with access to high-quality care and education, enhancing the delivery of men's health solutions [4]. Product Details - KYZATREX® is an oral formulation of testosterone undecanoate, primarily absorbed via the lymphatic system, which minimizes liver toxicity [6]. - Clinical studies have shown that KYZATREX is up to 96% effective in restoring testosterone levels, with 88% of participants achieving normal testosterone levels by Day 90 [3][8]. - The product is indicated for adult males with low or absent endogenous testosterone levels due to specific medical conditions [10]. Market Implications - The collaboration aims to address the underdiagnosed condition of testosterone deficiency, which affects men's health and quality of life, by leveraging Hims & Hers' digital platform and patient education resources [2][4]. - This partnership is expected to break down barriers to care, making innovative treatments more accessible and personalized for patients [4].